61,716 Shares in Lantheus Holdings, Inc. $LNTH Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company purchased a new position in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the second quarter, HoldingsChannel reports. The institutional investor purchased 61,716 shares of the medical equipment provider’s stock, valued at approximately $6,847,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Western Wealth Management LLC acquired a new position in shares of Lantheus during the 1st quarter valued at about $25,000. Smartleaf Asset Management LLC boosted its position in shares of Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 197 shares during the last quarter. Parallel Advisors LLC boosted its position in shares of Lantheus by 122.6% in the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 298 shares during the last quarter. Osterweis Capital Management Inc. purchased a new stake in Lantheus in the second quarter valued at approximately $36,000. Finally, Bessemer Group Inc. grew its holdings in Lantheus by 221.2% in the first quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 354 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

NASDAQ LNTH opened at $100.77 on Monday. Lantheus Holdings, Inc. has a one year low of $49.67 and a one year high of $111.86. The company’s 50 day moving average price is $103.74 and its 200 day moving average price is $91.76. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. The firm has a market capitalization of $6.58 billion, a price-to-earnings ratio of 24.34 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The company had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. During the same period in the previous year, the firm earned $1.57 earnings per share. Lantheus’s revenue for the quarter was up 2.7% on a year-over-year basis. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 4.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently commented on LNTH. Mizuho dropped their price target on shares of Lantheus from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Wednesday, July 29th. TD Cowen cut shares of Lantheus from a “buy” rating to a “hold” rating and lowered their price objective for the company from $110.00 to $102.50 in a research note on Monday, August 3rd. Leerink Partners set a $102.50 price objective on Lantheus in a report on Monday, August 3rd. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Finally, CJS Securities cut Lantheus from a “market outperform” rating to a “market perform” rating in a report on Tuesday, August 4th. Four equities research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $108.11.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.